Switch to:
More From Other Websites
Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017... Apr 21 2017
Should You Make a Bet on the Healthcare Stocks? Apr 18 2017
Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug Apr 13 2017
Pharma companies are seeking a new treatment — for the backlash against high drug prices Apr 13 2017
Company News for April 13, 2017 Apr 13 2017
Blog Coverage Neurocrine Stock Price Rocketed 25% After FDA's First Ever Approval for its Drug for... Apr 13 2017
Neurocrine Avoids Suicide Warning In Teva-Rivaling Drug; Stock Pops Apr 12 2017
Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder Apr 12 2017
HP Hits 2-Year High On Upgrade; GrubHub, Neurocrine Touted Apr 12 2017
NBIX: INGREZZA™ Approved by the FDA Apr 12 2017
Here's Why Neurocrine (NBIX) Stock is Soaring 24% Today Apr 12 2017
Neurocine Biosciences gets FDA approval for new drug Apr 12 2017
Approval For Neurocrine's Ingrezza Was No Surprise, But Lack Of Warning Label A Big Advantage Over... Apr 12 2017
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside Apr 12 2017
Why Neurocrine Biosciences Stock Is Soaring Higher Today Apr 12 2017
FDA Approves Neurocrine Biosciences Movement Disorder Therapy Apr 12 2017
Neurocrine Biosciences Wins Big With FDA Approval Apr 12 2017
Neurocrine Biosciences Achieves Best Case Scenario With Ingrezza Approval Apr 12 2017
Biotech Movers: Neurocrine Biosciences Leaps on Drug Approval, Synergy Pharma Issued Three Patents Apr 12 2017
Neurocrine Biosciences gets FDA's OK for movement disorder drug Apr 11 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK